Patents Examined by L. Blaine Lankford
  • Patent number: 8246947
    Abstract: Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: August 21, 2012
    Assignee: Cytori Therapeutics, Inc.
    Inventors: Marc H. Hedrick, John K. Fraser
  • Patent number: 8143059
    Abstract: The present invention relates to novel immortalized precursor cell populations derived from embryonic stem cell populations and methods to produce such cell populations. Also disclosed is an assay to identify regulatory compounds capable of controlling cell growth for therapeutic and experimental use.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: March 27, 2012
    Assignee: National Jewish Health
    Inventors: Gordon M. Keller, Robert G. Hawley, Kyunghee Choi
  • Patent number: 8119121
    Abstract: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: February 21, 2012
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick
  • Patent number: 7901914
    Abstract: Known microbiological methods are based upon the application of pigment-forming bacteria, in particular Chromobacterium violaceum. The yield of these methods is very low, however, so that large industrial applications are not possible. However, in many fields of industry, there exists a very great demand for natural blue dyes which are substantially suitable for human digestion, which cannot be satisfied at present. Therefore, the method in accordance with the invention is characterized by the application of the newly discovered marine sediment bacterium Pseudoalteromonas species of the “Black Beauty” strain (originally deposited under file number DSM 13623 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH., Braunschweig, Germany pursuant to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure). Compared to conventional methods, this marine sediment bacterium leads to an about thirteen-fold yield.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: March 8, 2011
    Assignee: Stiftung Alfred-Wegener-Institut fuer Polar- und Meeresforschung
    Inventors: Tjhing-Lok Tan, Franz-Peter Montforts, Daniela Meyer
  • Patent number: 7855062
    Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: December 21, 2010
    Assignee: The Invention Science Fund I, LLC
    Inventors: Ed Harlow, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
  • Patent number: 7838289
    Abstract: The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: November 23, 2010
    Assignees: ABT Holding Company, Regents of the University of Minnesota
    Inventors: Leo T. Furcht, Catherine M. Verfaillie, Morayma Reyes
  • Patent number: 7837992
    Abstract: A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: November 23, 2010
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Victor Gurewich, Ralph Pannell
  • Patent number: 7824673
    Abstract: A simple search was made on the Internet. There were at least a few hundred entries. The following seem to be the best of the few dozen examined. The first page of each is cited below for identification.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: November 2, 2010
    Assignee: Advance Biofactures Corporation
    Inventors: Edwin H. Wegman, Burton Bronsther, Ellyn Bronsther, legal representative
  • Patent number: 7785858
    Abstract: The present invention provides a bacterium which has an ability to produce a useful metabolite derived from acetyl-coenzyme A, such as L-glutamic acid, L-glutamine, L-proline, L-arginine, L-leucine, L-cysteine, succinate, and polyhydroxybutyrate, wherein said bacterium is modified so that activities of D-xylulose-5-phosphate phosphoketolase and/or fructose-6-phosphate phosphoketolase are enhanced. The present invention also provides a method for producing the useful metabolite using the bacterium.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: August 31, 2010
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yury Ivanovich Kozlov, Akito Chinen, Hiroshi Izui, Yoshihiko Hara, Hisashi Yasueda, Konstantin Vyacheslavovich Rybak, Ekaterina Aleksandrovna Slivinskaya, Joanna Yosifovna Katashkina
  • Patent number: 7785846
    Abstract: The present invention relates to a process for producing methionine by fermentation, a process for isolating the methionine formed, the methionine-containing biomass produced in isolation, use thereof for producing a feedstuff or feed supplement, and also to the use of the isolated methionine for producing foodstuffs or feedstuffs or food supplements or feed supplements.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: August 31, 2010
    Assignee: Evonik Degussa GmbH
    Inventors: Matthias Boy, Daniela Klein, Hartwig Schröder
  • Patent number: 7785633
    Abstract: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing hepatic dysfunction containing this agent. The agent for preventing or suppressing hepatic dysfunction of the present invention contains whey as the active component, and the functional food for preventing or suppressing hepatic dysfunction contains the agent for preventing or suppressing hepatic dysfunction.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: August 31, 2010
    Assignee: Calpis Co., Ltd
    Inventors: Yoshinori Moriyama, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Teppei Nakamura
  • Patent number: 7776579
    Abstract: Disclosed is an agent for digesting a protein highly resistant to denaturation and degradation, comprising as an active ingredient an enzyme exhibiting an activity of digesting a protein highly resistant to denaturation and degradation and having the following properties: (a) activity and substrate specificity: hydrolyzing a peptide bond of a protein highly resistant to denaturation and degradation; (b) molecular weight: 31,000 (determined by SDS-polyacrylamide gel electrophoresis using a homogeneous gel having a gel concentration of 12%); (c) isoelectric point: pI 9.3 (determined by polyacrylamide gel isoelectric focusing electrophoresis); (d) optimum pH: pH 9.0 to 10.0; and (e) optimum temperature for activity: 60 to 70° C.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: August 17, 2010
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Takehiro Miwa, Koji Nishizawa, Yoshie Hayashi, Manabu Watanabe, Yuichi Murayama, Miyako Yoshioka, Katsuhiro Miura
  • Patent number: 7771754
    Abstract: Methods and devices to process harvested skin tissue and reintroduction of the ground tissue to repair a tissue defect are disclosed. A hand-held portable tissue grinder comprising a housing and a grinding element are disclosed. The tissue grinder is used for grinding skin and subcutaneous tissue and includes a sterile polymer housing having a first opening adapted to receive the skin and subcutaneous tissue and a second opening in fluid connection with the first opening. The tissue grinder also includes a sterile grinding element disposed substantially within the housing. The grinding element includes a plurality of cutting surfaces adapted to operably engage with the housing to provide ground tissue and further includes a handle mechanism coupled to the grinding element to move the grinding element with respect to the housing to grind the skin and subcutaneous tissue, wherein the ground tissue can be removed from the housing through the second opening.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 10, 2010
    Inventor: Omeed Memar
  • Patent number: 7767426
    Abstract: A method of producing riboflavin by culturing riboflavin-producing microbes in a culture medium using a plant oil or an animal oil as a carbon source, forming and accumulating riboflavin therein and collecting riboflavin therefrom, wherein a carrier of a clay mineral having oil-adsorbing property, a chemically treated product thereof or a calcium compound is made present in the culture medium. The riboflavin is produced maintaining a high yield and at an increased production rate at a low cost without requiring cumbersome operations for concentrating and recovering the riboflavin. It is further allowed to recover the riboflavin by effectively utilizing the waste plant oil or the waste animal oil that is to be disposed of.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: August 3, 2010
    Assignee: Mizusawa Industrial Chemicals, Ltd.
    Inventors: Kiyoshi Abe, Hiroshi Nitta, Enoch Y. Park, Hua Ming, Eun He Jung
  • Patent number: 7754232
    Abstract: The present invention provides a method of, and apparatus for, utilizing ultrasonic energy so as to mechanically disrupt the collagenous architecture of biological matrices in a controlled manner so that the tissue can be rapidly recellularized in continuous form. The present invention also provides for the production of tissue matrices with improved recellularization properties, cell stratification or patterning.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: July 13, 2010
    Assignee: The University of Leeds
    Inventors: John Fisher, Eileen Ingham
  • Patent number: 7754469
    Abstract: An isolated Bacillus strain LSSAO1 is provided. When fed to a bird, this and other Bacillus strains described herein provide benefits to the birds. For example, administration of the one or more Bacillus strain can increase low G+C, gram positive bacteria in the gastrointestinal flora of the bird. These type of bacteria are increased by antibiotics and include beneficial Clostridium. Administration of the one or more Bacillus strain can also inhibit pathogen in the bird, such as E. coli, Salmonella, and Clostridium. These benefits can enhance feed conversion in poultry. Useful combinations of Bacillus strains and methods of using one or more Bacillus strain are also provided.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: July 13, 2010
    Assignee: Agtech Products, Inc
    Inventors: Tammy Baltzley, Firmin Lago, Tony Neumann, Thomas Rehberger, Shelly Gebert
  • Patent number: 7754244
    Abstract: The present invention relates to composition useful in growing hair. The compositions are particularly suited for re-growing hair in subjects who have experienced hair loss due to any cause. The compositions comprise essentially the lipoidic fraction of mammalian bone marrow. Methods of using the compositions and processes of preparing the lipoidic fraction for the compositions are also disclosed.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: July 13, 2010
    Inventor: Fatemeh Mirzaee
  • Patent number: 7750053
    Abstract: Products and compositions for preventing or reducing the severity of hypertension. These products contain (a) ferulic acid or a ferulate ester, and (b) caffeic acid and/or a chlorogenic acid. The preventive or remedy can suppress a rise in blood pressure and alleviate hypertension, and is usable as a food.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: July 6, 2010
    Assignee: KAO Corporation
    Inventors: Atsushi Suzuki, Ryuji Ochiai, Ichiro Tokimitsu
  • Patent number: 7732184
    Abstract: Liquid microbial starter culture that retains its initial metabolic activity during storage for extended periods of time. Such liquid starter cultures are useful in the manufacturing of food and feed products. Starter cultures of the invention include culture of lactic acid bacteria, e.g. Lactococcus species.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: June 8, 2010
    Assignee: Chr. Hansen A/S
    Inventors: Boerge Kringelum, Lene Kragelund
  • Patent number: 7727751
    Abstract: The present invention relates to a process for the preparation of mycophenolate mofetil (MMF) in which an ester of mycophenolic acid (MPA) with a low-molecular-weight aliphatic alcohol is transesterified with N-(2-hydroxyethyl)morpholine in the presence of Candida antarctica lipase, and in which the MPA esterification reaction is carried out in the presence of Candida antarctica lipase using the corresponding alcohol as the solvent.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: June 1, 2010
    Assignee: Poli Industria Chimica SpA
    Inventors: Paride Grisenti, Paolo Prestileo